医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Brentuximab Vedotin

欧盟委员会核准ADCETRIS® (brentuximab vedotin)用于治疗既往未曾治疗的全身性间变性大细胞淋巴瘤成人患者

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin 全身性间变性大细胞淋巴瘤成人患者欧盟委员会核准ADCETRIS 治疗既往未曾治

2020年05月18日

European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin European Commission Approves ADCETRIS for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

2020年05月14日

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ADCETRIS Brentuximab Vedotin Cyclophosphamide Opinion for Takeda Receives Positive CHMP

2020年03月31日

Seattle Genetics和武田在ASH 2019年会上发布 ADCETRIS® (Brentuximab Vedotin) ECHELON-1和ECHELON-2 3期临床试验的追加分析结果

Seattle Genetics和武田在ASH 2019年会上发布 ADCETRIS® (Brentuximab Vedotin) ECHELON-1和ECHELON-2 3期临床试验的追加分析结果

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ADCETRIS Brentuximab Vedotin ECHELON-1和ECHELON-2 3期临床试 Seattle Genetics和武田在ASH 追加分析结果

2019年12月12日

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials Seattle Genetics and Takeda Announce Additional

2019年12月10日

欧盟委员会核准ADCETRIS® (brentuximab vedotin)联合AVD用于既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者，这是数十年来首个新治疗方案

欧盟委员会核准ADCETRIS® (brentuximab vedotin)联合AVD用于既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者，这是数十年来首个新治疗方案

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Brentuximab Vedotin

2019年02月14日

European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Adults with Previously Untreated CD30 Brentuximab Vedotin European Commission Approves ADCETRIS Stage IV Hodgkin Lymphoma the First New Treatment in Decades for

2019年02月11日

武田获得CHMP肯定意见，接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者

武田获得CHMP肯定意见，接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者

バイオテクノロジーヘルスケアヘルス一般幹細胞腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin

2018年12月18日

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

バイオテクノロジーヘルスケアヘルス一般幹細胞腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin For the Treatment of Adult Patients Previously Untreated CD30 Stage IV Hodgkin Lymphoma in Combination Takeda Receives Positive CHMP Opinion for ADCETRIS

2018年12月15日

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin ECHELON-2 Clinical Trial for ADCETRIS in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas Seattle Genetics and Takeda Present Positive Data

2018年12月04日